Sat, March 8, 2025
[ Sat, Mar 08th ] - CNBC
The Look Ahead: March 7, 2025
Fri, March 7, 2025
Thu, March 6, 2025
Wed, March 5, 2025
Tue, March 4, 2025
Mon, March 3, 2025
Sun, March 2, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2024 Earnings Call Transcript


//business-finance.news-articles.net/content/202 .. asdaq-ocul-q4-2024-earnings-call-transcript.html
Published in Business and Finance on by MSN   Print publication without navigation

Q4 2024 Earnings Call Transcript March 3, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is $-0.29 EPS, expectations were $-0.24. Operator: Good morning, and welcome to the Ocular Therapeutix Fourth Quarter 2024 Earnings Conference Call.

The article provides a transcript of the Q4 2024 earnings call for Ocular Therapeutix Inc., a biopharmaceutical company focused on eye care. During the call, CEO Antony Mattessich and CFO Donald Notman discussed the company's financial performance, operational updates, and future outlook. Key points included the progress of their lead product candidate, OTX-TKI, for the treatment of wet age-related macular degeneration (wet AMD), with positive interim data from the ongoing Phase 1 HELIOS trial. They also touched on the development of other pipeline products, strategic partnerships, and the company's efforts to manage costs while advancing their clinical programs. The call highlighted a focus on innovation in ophthalmic treatments, aiming to address unmet medical needs in eye diseases.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/savingandinvesting/ocular-therapeutix-inc-nasdaq-ocul-q4-2024-earnings-call-transcript/ar-AA1AdUnD ]

Publication Contributing Sources